Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night’s $35.98 close.
The company’s 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.
The Chelmsford, Mass.-based resuscitation devices maker also logged record earnings of $31.3 million, 65 percent over 2010 profits of $19 million. Earnings per share jumped 60 percent from last year’s 87 cents to $1.39 for 2011.
In a separate release, Zoll also announced a $50 million stock buyback allowance.
"We have ample liquidity, no debt, and generated in excess of $40 million in cash from operating activities during our 2011 fiscal year,” CEO Richard Packer said in a press release. "We are pleased that our strong balance sheet allows us to demonstrate our confidence in our future prospects, without sacrificing our pursuit of those business opportunities in front of us.
“2011 was a very strong year for ZOLL. Our annual revenues exceeded $520 million for the first time, making us the clear leader in the resuscitation market," Packer added in prepared remarks. "We were particularly happy to outperform our bottom-line. The key revenue drivers included a strengthening of our core defibrillator business along with continued growth in both our LifeVest and Temperature Management businesses.”
The biggest sales boost came from Zoll’s LifeVest device, the only wearable cardiac defibrillator on the market in the U.S., which contributed $111 million for the year, a 57 percent jump compared to $70.7 million for 2010.
The company’s temperature management business followed, up 38 percent jump to $26 million, compared to last year’s $18.9 million.
The surge on The Street still doesn’t bring Zoll back from a 27 percent slide following news in August of a Centers for Medicare & Medicaid Services review of the reimbursement scheme for the LifeVest.
Zoll’s shares dropped hard and fast after that news, to close at $44.46 August 8, down 27 percent. The company had set a high-water mark just a week earlier, opening at $70.82 August 1 after a strong third-quarter earnings report.
Shares moved up on news earlier this week that North Carolina’s Division of Medical Assistance approved Medicaid coverage for LifeVest.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup.
Bovie Medical’s Q3 profits soar despite sales slide
Bovie Medical (NYSE:BVX) boosted third-quarter profits by 1,475 percent despite a 3.8 percent sales decline
The Melville, N.Y.-based electro-surgical device maker reported profits of $63,000, or no earnings per share, on sales of $6.3 million for the three months ended Sept. 30.
That compares with profits of $4,000, also no earnings per share, on sales of $6.5 million during the same period last year. Read more
Cardium Therapeutics pares Q3 losses
Cardium Therapeutics (NYSE:CXM) managed to pare its third-quarter losses by 53.6 percent despite posting no revenues for the period.
The San Diego-based cardiac treatment developer reported losses of $1.6 million, or 2 cents per share, for the three months ended Sept. 30, compared with losses of $3.4 million, or 4 cents per share, during the same period last year. Read more
Daxor Corp. swings to Q3 loss
Daxor Corp. (NYSE:DXR) swung to third-quarter losses on a 24.8 percent sales slide.
The New York-based blood volume device maker reported losses of $4.2 million, or 99 cents per share, on sales of $341,000 for the three months ended Sept. 30.
That compares with profits of $2.6 million, or 62 cents per share, on sales of $453,000 during the same period last year. Read more
Derma Sciences grows Q3 sales, losses
Derma Sciences (NSDQ:DSCI) posted sales growth of 5 percent but saw losses widen by 44.5 percent during the third quarter
The Princeton, N.J.-based wound care firm reported losses of $789,000, or 8 cents per share, on sales of $15.8 million for the three months ended Sept. 30.
That compares with losses of $546,000, also 8 cents per share, on sales of $15.1 million during the same period last year. Read more
Edap swings to Q3 profits
Edap TMS SA (NSDQ:EDAP) put some black ink in its ledger for the third quarter on sales growth of 22.8 percent.
The Lyon, France-based ultrasound device maker reported profits of $1.2 million, or 9 cents per share, on sales of $8.6 million for the three months ended Sept. 30.
That compares with losses of $2.5 million, or 22 cents per share, on sales of $7.0 million during the same period last year. Read more
Fonar Corp.’s Q1 sales, earnings rise
Fonar Corp. (NSDQ:FONR) boosted first-quarter sales by 10.6 percent and increased profits by 360.3 percent.
The Melville, N.Y.-based MRI device maker reported profits of $1.8 million, or 25 cents per share, on sales of $9.6 million for the three months ended Sept. 30.
That compares with profits of $385,000, or 7 cents per share, on sales of $8.7 million during the same period last year. Read more
Sales plunge as Imris swings to Q3 red
Third-quarter sales for Imris Inc. (NSDQ:IMRS) plunged 57.1 percent, pushing the company into red ink territory.
The Winnipeg-based imaging solutions maker reported losses of $8.5 million, or 19 cents per share, on sales of $7.2 million for the three months ended Sept. 30.
That compares with profits of $744,000, or 2 cents per share, on sales of $16.8 million during the same period last year. Read more
InspireMD’s Q3 sales, losses increase
InspireMD logged sales growth of 62.4 percent but saw losses widen by 169.5 percent for the third quarter.
The Tel Aviv-based stent maker reported losses of $2.3 million, or 4 cents per share, on sales of $2.0 million for the three months ended Sept. 30.
That compares with profits of $847,000, or 2 cents per share, on sales of $1.2 million during the same period last year. Read more
Oridion’s Q3 sales, earnings rise
Oridion Systems (SWF:ORIDN) raised sales and earnings during the third quarter.
The Jerusalem-based capnography maker reported profits of $2.8 million on sales of $16.8 million for the three months ended Sept. 30.
That compares with profits of $1.9 million on sales of $13.8 million during the same period last year. Read more
Sales down as Patient Safety Technologies swings to Q3 loss
Patient Safety Technologies (PINK:PSTX) saw third-quarter sales decline as it swung to red ink.
The Irvine, Calif.-based SurgiCount Medical parent reported losses of $354,000, or 1 cent per share, on sales of $2.2 million for the three months ended Sept. 30.
That compares with profits of $962,000, or 4 cents per share, on sales of $4.1 million during the same period last year. Read more
PLC Systems boosts Q3 sales, losses soar
Third-quarter losses soared for PLC Systems (OTC:PLCSF) despite a 58.8 percent sales increase.
The Milford, Mass.-based device maker reported losses of $401,000, or 1 cent per share, on sales of $27,000 for the three months ended Sept. 30.
That compares with losses of $5,000, or no earnings per share, on sales of $17,000 during the same period last year. Read more
Sanuwave cuts Q3 losses despite lower sales
Sanuwave Health (OTC:SNWV) managed to pare 23.2 percent from its third-quarter losses despite a 41.9 percent sales slide.
The Alpharetta, Ga.-based regenerative medicine company reported losses of $2.1 million, or 10 cents per share, on sales of $162,000 for the three months ended Sept. 30.
That compares with losses of $2.7 million, or 21 cents per share, on sales of $278,000 during the same period last year. Read more
Tengion’s Q3 losses mount
Tengion’s third-quarter losses increased by nearly 600 percent.
The East Norriton, Pa.-based regenerative medicine firm reported losses of $6.7 million, or 54 cents per share, for the three months ended Sept. 30.
That compares with losses of $960,000, or 4 cents per share during the same period last year. Read more
